No Differences of Immune Activation and Microbial Translocation Among HIV-infected Children Receiving Combined Antiretroviral Therapy or Protease Inhibitor Monotherapy

This is a cross-sectional study of 15 aviremic chronic HIV-infected children revealing no differences in immune activation (IA; HLA-DR(+)CD38(+) CD4(+) and CD8(+) T cells, and sCD14) and microbial translocation (MT; lipopolysaccharides (LPS) and 16S rDNA) among HIV-infected patients under combined a...

Descripción completa

Detalles Bibliográficos
Autores principales: Falcon-Neyra, Lola, Benmarzouk-Hidalgo, Omar J., Madrid, Lola, Noguera-Julian, Antoni, Fortuny, Claudia, Neth, Olaf, López-Cortés, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
6200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602495/
https://www.ncbi.nlm.nih.gov/pubmed/25789946
http://dx.doi.org/10.1097/MD.0000000000000521
Descripción
Sumario:This is a cross-sectional study of 15 aviremic chronic HIV-infected children revealing no differences in immune activation (IA; HLA-DR(+)CD38(+) CD4(+) and CD8(+) T cells, and sCD14) and microbial translocation (MT; lipopolysaccharides (LPS) and 16S rDNA) among HIV-infected patients under combined antiretroviral treatment (cART; n = 10) or ritonavir-boosted protease inhibitor monotherapy (mtPI/rtv; n = 5). In both cases, IA and MT were lower in healthy control children (n = 32). This observational study suggests that ritonavir boosted protease inhibitor monotherapy (mtPI/rtv) is not associated with an increased state of IA or MT as compared with children receiving cART.

Ejemplares similares